Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway

Chronic myelogenous leukemia (CML) is a common hematological malignancy. Some patients progressing to the blast phase develop chemotherapeutic drug resistance. In the authors' previous study, it was found that the mammalian target of rapamycin (mTOR) pathway was activated in CML and that rapamy...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncol Lett
Asıl Yazarlar: Li, Jie, Liu, Wenjing, Hao, Hongling, Wang, Qiuyi, Xue, Liying
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2019
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6676723/
https://ncbi.nlm.nih.gov/pubmed/31404320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.10589
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller